ADPT
Adaptive Biotechnologies Corpor
$13.81
-5.99%
2026-05-08
About Adaptive Biotechnologies Corpor
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Key Fundamentals
Forward P/E
-51.17
EPS (TTM)
$-0.32
ROE
-24.0%
Revenue Growth (YoY)
35.1%
Profit Margin
-16.8%
Debt/Equity
92.84
Price/Book
9.83
Beta
2.16
Market Cap
$2.24B
Avg Volume (10D)
1.9M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$16.95
60D Low
$12.00
Avg Volume
1.9M
Latest Close
$13.81
Get breakout alerts for ADPT
Sign up for Breakout Scanner to receive daily notifications when ADPT triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Adaptive Biotechnologies Corpor (ADPT) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors ADPT daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. ADPT operates in the Healthcare sector within the Diagnostics & Research industry. Data is provided for informational purposes only and does not constitute financial advice.